Concepts (186)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Emergency Service, Hospital | 5 | 2021 | 535 | 1.690 |
Why?
|
| Patient Readmission | 3 | 2021 | 367 | 1.500 |
Why?
|
| Social Determinants of Health | 2 | 2021 | 106 | 1.260 |
Why?
|
| Heart Failure | 5 | 2021 | 1273 | 1.230 |
Why?
|
| Violence | 2 | 2021 | 155 | 1.230 |
Why?
|
| Hemorrhage | 2 | 2017 | 290 | 0.940 |
Why?
|
| Troponin T | 1 | 2021 | 39 | 0.730 |
Why?
|
| Endothelium, Vascular | 4 | 2013 | 435 | 0.730 |
Why?
|
| Acute Coronary Syndrome | 1 | 2021 | 31 | 0.700 |
Why?
|
| Cardiovascular Diseases | 3 | 2021 | 733 | 0.690 |
Why?
|
| Office Visits | 1 | 2020 | 50 | 0.690 |
Why?
|
| Community Health Workers | 1 | 2020 | 35 | 0.680 |
Why?
|
| Blood Pressure | 2 | 2021 | 908 | 0.640 |
Why?
|
| Urban Population | 1 | 2020 | 227 | 0.640 |
Why?
|
| Critical Pathways | 1 | 2017 | 37 | 0.580 |
Why?
|
| Endothelial Cells | 3 | 2016 | 471 | 0.530 |
Why?
|
| Angiopoietin-2 | 1 | 2016 | 18 | 0.530 |
Why?
|
| Cardiology | 1 | 2017 | 122 | 0.510 |
Why?
|
| Mesenteric Artery, Superior | 1 | 2014 | 19 | 0.470 |
Why?
|
| Protein Kinase C | 2 | 2012 | 267 | 0.460 |
Why?
|
| Posture | 1 | 2014 | 124 | 0.460 |
Why?
|
| Catheterization, Peripheral | 1 | 2014 | 60 | 0.450 |
Why?
|
| Neovascularization, Pathologic | 1 | 2016 | 354 | 0.450 |
Why?
|
| Patient Positioning | 1 | 2014 | 66 | 0.440 |
Why?
|
| Patient Education as Topic | 1 | 2017 | 368 | 0.440 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2014 | 82 | 0.440 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2014 | 110 | 0.440 |
Why?
|
| Hypertension | 1 | 2019 | 757 | 0.440 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 705 | 0.440 |
Why?
|
| Aged | 12 | 2021 | 19574 | 0.430 |
Why?
|
| Brachial Artery | 2 | 2013 | 37 | 0.420 |
Why?
|
| Vasodilation | 2 | 2013 | 93 | 0.410 |
Why?
|
| Diabetic Angiopathies | 1 | 2012 | 37 | 0.410 |
Why?
|
| Heart-Assist Devices | 2 | 2017 | 825 | 0.400 |
Why?
|
| Sulfasalazine | 1 | 2012 | 34 | 0.400 |
Why?
|
| Middle Aged | 14 | 2021 | 26555 | 0.390 |
Why?
|
| Fingers | 1 | 2012 | 69 | 0.380 |
Why?
|
| Nitric Oxide Synthase Type III | 4 | 2018 | 89 | 0.350 |
Why?
|
| Coronary Artery Disease | 2 | 2013 | 374 | 0.350 |
Why?
|
| Chicago | 3 | 2021 | 1452 | 0.350 |
Why?
|
| Risk Factors | 4 | 2021 | 5608 | 0.340 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2012 | 243 | 0.340 |
Why?
|
| Retrospective Studies | 6 | 2021 | 9399 | 0.330 |
Why?
|
| Male | 15 | 2021 | 43249 | 0.310 |
Why?
|
| Humans | 20 | 2021 | 91073 | 0.310 |
Why?
|
| Tertiary Care Centers | 2 | 2021 | 114 | 0.310 |
Why?
|
| Insulin | 1 | 2012 | 1161 | 0.290 |
Why?
|
| Biomarkers | 4 | 2021 | 1814 | 0.280 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2012 | 1204 | 0.280 |
Why?
|
| Female | 14 | 2021 | 47186 | 0.270 |
Why?
|
| Postoperative Complications | 1 | 2017 | 2348 | 0.270 |
Why?
|
| Socioeconomic Factors | 2 | 2020 | 596 | 0.260 |
Why?
|
| Signal Transduction | 2 | 2012 | 3442 | 0.230 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 1750 | 0.220 |
Why?
|
| Ultrasonography, Doppler | 2 | 2014 | 85 | 0.210 |
Why?
|
| Diabetes Mellitus | 1 | 2010 | 751 | 0.210 |
Why?
|
| Case-Control Studies | 2 | 2017 | 1877 | 0.210 |
Why?
|
| Nitric Oxide | 3 | 2018 | 281 | 0.200 |
Why?
|
| Adult | 8 | 2021 | 27147 | 0.190 |
Why?
|
| Protein Kinase C beta | 2 | 2012 | 14 | 0.190 |
Why?
|
| Crime | 1 | 2021 | 37 | 0.190 |
Why?
|
| Patient Admission | 1 | 2021 | 113 | 0.180 |
Why?
|
| Glomerular Filtration Rate | 1 | 2021 | 280 | 0.170 |
Why?
|
| Residence Characteristics | 1 | 2021 | 204 | 0.170 |
Why?
|
| NF-kappa B | 2 | 2012 | 469 | 0.160 |
Why?
|
| Time Factors | 3 | 2019 | 5378 | 0.160 |
Why?
|
| Insulin Resistance | 2 | 2012 | 374 | 0.160 |
Why?
|
| Perioperative Care | 1 | 2021 | 172 | 0.160 |
Why?
|
| Illinois | 1 | 2020 | 499 | 0.160 |
Why?
|
| Academic Medical Centers | 1 | 2021 | 388 | 0.150 |
Why?
|
| Oxidative Stress | 2 | 2012 | 464 | 0.150 |
Why?
|
| Hospitals | 1 | 2021 | 309 | 0.150 |
Why?
|
| Neuroprotection | 1 | 2018 | 9 | 0.150 |
Why?
|
| Hospital Costs | 1 | 2019 | 113 | 0.150 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2021 | 230 | 0.150 |
Why?
|
| Sex Factors | 1 | 2021 | 1082 | 0.150 |
Why?
|
| Organizational Case Studies | 1 | 2017 | 28 | 0.140 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 1 | 2019 | 94 | 0.140 |
Why?
|
| Cost Control | 1 | 2017 | 45 | 0.140 |
Why?
|
| Urban Health | 1 | 2017 | 56 | 0.140 |
Why?
|
| Interprofessional Relations | 1 | 2017 | 121 | 0.140 |
Why?
|
| Mitochondria | 2 | 2011 | 562 | 0.140 |
Why?
|
| rho-Associated Kinases | 1 | 2018 | 160 | 0.130 |
Why?
|
| Age Factors | 1 | 2021 | 1876 | 0.130 |
Why?
|
| Atrial Fibrillation | 1 | 2021 | 361 | 0.130 |
Why?
|
| Propensity Score | 1 | 2017 | 156 | 0.130 |
Why?
|
| Thrombin | 1 | 2016 | 61 | 0.130 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2016 | 70 | 0.130 |
Why?
|
| Soybean Oil | 1 | 2016 | 2 | 0.130 |
Why?
|
| Incidence | 1 | 2020 | 1599 | 0.130 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2019 | 224 | 0.130 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 1093 | 0.130 |
Why?
|
| Arteriovenous Malformations | 1 | 2016 | 45 | 0.130 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2019 | 198 | 0.130 |
Why?
|
| Kidney | 1 | 2021 | 1153 | 0.130 |
Why?
|
| Phospholipids | 1 | 2016 | 112 | 0.120 |
Why?
|
| Health Status | 1 | 2017 | 370 | 0.120 |
Why?
|
| Leg | 1 | 2016 | 140 | 0.120 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2016 | 88 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 854 | 0.120 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 1169 | 0.120 |
Why?
|
| Acute Disease | 1 | 2017 | 855 | 0.120 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2016 | 207 | 0.120 |
Why?
|
| Subclavian Artery | 1 | 2014 | 43 | 0.120 |
Why?
|
| Radiography, Abdominal | 1 | 2014 | 70 | 0.110 |
Why?
|
| Referral and Consultation | 1 | 2017 | 352 | 0.110 |
Why?
|
| Patient Discharge | 1 | 2017 | 328 | 0.110 |
Why?
|
| Communication | 1 | 2017 | 462 | 0.110 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2013 | 22 | 0.110 |
Why?
|
| Sample Size | 1 | 2013 | 125 | 0.110 |
Why?
|
| Mesylates | 1 | 2012 | 15 | 0.100 |
Why?
|
| Blood Vessels | 1 | 2013 | 94 | 0.100 |
Why?
|
| Ventricular Function, Right | 1 | 2013 | 150 | 0.100 |
Why?
|
| Boston | 1 | 2012 | 37 | 0.100 |
Why?
|
| Manometry | 1 | 2012 | 44 | 0.100 |
Why?
|
| Risk Assessment | 1 | 2019 | 2345 | 0.100 |
Why?
|
| Hospitalization | 1 | 2017 | 903 | 0.100 |
Why?
|
| Peripheral Arterial Disease | 1 | 2013 | 98 | 0.100 |
Why?
|
| Pyrroles | 1 | 2012 | 171 | 0.100 |
Why?
|
| Health Care Costs | 1 | 2013 | 238 | 0.100 |
Why?
|
| Antihypertensive Agents | 1 | 2013 | 258 | 0.090 |
Why?
|
| Inflammation Mediators | 1 | 2012 | 155 | 0.090 |
Why?
|
| Cross-Over Studies | 1 | 2012 | 388 | 0.090 |
Why?
|
| Leukocytes | 1 | 2012 | 209 | 0.090 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 1753 | 0.090 |
Why?
|
| Cells, Cultured | 2 | 2012 | 2891 | 0.090 |
Why?
|
| Diagnosis, Differential | 1 | 2014 | 1609 | 0.090 |
Why?
|
| Analysis of Variance | 1 | 2012 | 897 | 0.080 |
Why?
|
| Hypoglycemic Agents | 1 | 2012 | 360 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 1063 | 0.080 |
Why?
|
| Young Adult | 2 | 2019 | 6502 | 0.080 |
Why?
|
| Diagnostic Imaging | 1 | 2013 | 475 | 0.080 |
Why?
|
| Hypertension, Pulmonary | 1 | 2013 | 371 | 0.080 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2010 | 268 | 0.080 |
Why?
|
| Double-Blind Method | 1 | 2012 | 1738 | 0.070 |
Why?
|
| Adolescent | 1 | 2019 | 9411 | 0.070 |
Why?
|
| Atherosclerosis | 1 | 2010 | 263 | 0.070 |
Why?
|
| Phosphorylation | 2 | 2018 | 1131 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 2711 | 0.060 |
Why?
|
| Inflammation | 1 | 2010 | 998 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 2 | 2019 | 481 | 0.050 |
Why?
|
| Treatment Outcome | 2 | 2013 | 8436 | 0.050 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2019 | 148 | 0.040 |
Why?
|
| Peptide Elongation Factor 1 | 1 | 2018 | 11 | 0.040 |
Why?
|
| Activating Transcription Factor 6 | 1 | 2016 | 5 | 0.030 |
Why?
|
| Transcription Factor CHOP | 1 | 2016 | 14 | 0.030 |
Why?
|
| Hyperemia | 1 | 2016 | 19 | 0.030 |
Why?
|
| Emulsions | 1 | 2016 | 19 | 0.030 |
Why?
|
| X-Box Binding Protein 1 | 1 | 2016 | 21 | 0.030 |
Why?
|
| Protein Phosphatase 1 | 1 | 2016 | 34 | 0.030 |
Why?
|
| Microcirculation | 1 | 2016 | 105 | 0.030 |
Why?
|
| Animals | 2 | 2018 | 27783 | 0.030 |
Why?
|
| Length of Stay | 1 | 2019 | 758 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2016 | 147 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2018 | 727 | 0.030 |
Why?
|
| Endoribonucleases | 1 | 2016 | 94 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2016 | 419 | 0.030 |
Why?
|
| Heparin | 1 | 2016 | 186 | 0.030 |
Why?
|
| Registries | 1 | 2019 | 826 | 0.030 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2013 | 65 | 0.030 |
Why?
|
| Models, Economic | 1 | 2013 | 63 | 0.030 |
Why?
|
| Cost Savings | 1 | 2013 | 71 | 0.030 |
Why?
|
| Brain Ischemia | 1 | 2018 | 399 | 0.030 |
Why?
|
| Massachusetts | 1 | 2013 | 34 | 0.030 |
Why?
|
| Nitroglycerin | 1 | 2013 | 23 | 0.030 |
Why?
|
| Blood Flow Velocity | 1 | 2013 | 200 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2016 | 440 | 0.030 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2013 | 165 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2013 | 804 | 0.020 |
Why?
|
| Cyclic GMP | 1 | 2011 | 62 | 0.020 |
Why?
|
| Free Radical Scavengers | 1 | 2011 | 59 | 0.020 |
Why?
|
| GTP Phosphohydrolases | 1 | 2011 | 75 | 0.020 |
Why?
|
| Dynamins | 1 | 2011 | 50 | 0.020 |
Why?
|
| Mitochondrial Proteins | 1 | 2011 | 128 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2011 | 184 | 0.020 |
Why?
|
| Aorta | 1 | 2011 | 291 | 0.020 |
Why?
|
| Comorbidity | 1 | 2013 | 963 | 0.020 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2013 | 521 | 0.020 |
Why?
|
| Glucose | 1 | 2011 | 630 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2011 | 494 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2011 | 784 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 1993 | 0.020 |
Why?
|
| Cell Line | 1 | 2011 | 2506 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2011 | 1237 | 0.010 |
Why?
|
| Mice | 1 | 2018 | 11993 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2013 | 6847 | 0.010 |
Why?
|